FNP Pharmacology Review: 10 High-Yield Board Concepts

Pharmacology · 9 min read · June 25, 2026

#10 High-Yield Pharmacology Concepts Every FNP Student Should Know for Boards

Updated June 2026

You know what lisinopril does. You recognize metformin. You can identify a statin by its name.

Then the question asks:

“What should the nurse practitioner do next?”

That is where pharmacology gets difficult.

Board-style medication questions rarely depend on recalling every adverse effect in a drug monograph. They usually test whether you can make one of four decisions:

Is this an expected effect or a dangerous reaction?
Should the medication be continued, held, tapered, or stopped?
What laboratory value or symptom should be monitored?
What patient teaching prevents harm?

The fastest way to improve your pharmacology performance is to stop studying medications as isolated lists. Study them as clinical decisions.

Here are 10 high-yield concepts that commonly cause confusion—along with the details and board traps you actually need to know.

Study note: This article is for board review and education. Patient-specific decisions should follow current prescribing information, clinical guidelines, and local protocols.

1. ACE Inhibitors: Know the Difference Between Cough and Angioedema

The Typical Question

A patient started lisinopril several weeks ago and now reports a dry, persistent cough. The patient has no fever, shortness of breath, wheezing, or abnormal lung findings.

What should the NP do?

The Best Answer

Recognize the cough as an ACE inhibitor class effect. Discontinue the ACE inhibitor and, when continued renin-angiotensin system blockade is appropriate, consider an ARB such as losartan or valsartan.

Do not simply change lisinopril to another medication ending in “-pril.” The cough is associated with the entire ACE inhibitor class, not one particular drug.

Why It Happens

ACE inhibition reduces the breakdown of bradykinin. Bradykinin accumulation can produce the characteristic persistent, nonproductive cough. The cough generally resolves after the ACE inhibitor is discontinued. (DailyMed)

The Board Trap: Cough Is Not Angioedema

A dry cough is uncomfortable, but it is not usually an emergency.

Swelling of the lips, tongue, face, glottis, or larynx is different. That suggests ACE inhibitor–associated angioedema. The ACE inhibitor should be stopped immediately, and airway involvement requires urgent or emergency management. Do not treat that scenario as a routine medication switch. (DailyMed)

Memory Hook

ACE = Annoying Cough Expected.

But remember:

Cough = change the class. Swelling = protect the airway.

2. Metformin and Contrast: Stop Memorizing the Universal 48-Hour Rule

The Typical Question

A patient taking metformin is scheduled for a CT scan with iodinated IV contrast. Should metformin be stopped?

The Best Answer

It depends on:

The patient’s kidney function
Whether acute kidney injury is present
Whether contrast is being given intravenously or through an arterial catheter
Which guideline, labeling standard, or institutional protocol the question is using

The old rule—“hold metformin for 48 hours before and after every contrast study”—is too broad.

What the ACR Recommends

Under the 2026 American College of Radiology guidance:

Clinical situation	Metformin management
No AKI and eGFR ≥30 mL/min/1.73 m²; routine IV iodinated contrast	Metformin does not need to be stopped before or after the study, and a routine postprocedure renal-function check is not required
AKI, eGFR <30, or an arterial catheter study that could send emboli to the renal arteries	Stop metformin at or before the procedure, hold it for 48 hours afterward, and restart only after renal function has been reassessed and is acceptable

Iodinated contrast does not directly interact with metformin. The concern is that contrast-associated kidney injury could reduce metformin clearance, causing accumulation and increasing the risk of lactic acidosis.

Why Some Questions Give a Different Answer

FDA-approved metformin labeling is more conservative. It recommends stopping metformin at or before iodinated contrast in patients with an eGFR of 30–60, a history of liver disease, alcoholism or heart failure, or planned intra-arterial contrast. The eGFR should then be reassessed after 48 hours, with metformin restarted if renal function is stable. (DailyMed)

How to Answer This on Boards

Do not react to the word “contrast” alone. Look for:

eGFR
AKI
IV versus intra-arterial administration
Heart failure, liver disease, or alcohol misuse
A reference to ACR guidance, FDA labeling, or facility policy

Memory Hook

Contrast question? Check KIDNEY + ROUTE + PROTOCOL.

The clock matters only after you determine the patient’s risk category.

3. Warfarin Interactions: A New Medication Requires a New INR Plan

The Typical Question

A patient with a stable therapeutic INR begins metronidazole, trimethoprim-sulfamethoxazole, or fluconazole.

What is the priority?

The Best Answer

Anticipate a clinically important interaction and arrange more frequent INR monitoring. The warfarin dose may need adjustment based on the INR, treatment duration, baseline stability, and bleeding risk.

Metronidazole, TMP-SMX, and azole antifungals are commonly associated with an increased warfarin effect. The patient should also be counseled to report abnormal bruising, nosebleeds, hematuria, melena, severe headache, dizziness, or persistent bleeding.

The Important Nuance

Not every warfarin interaction raises the INR.

Rifampin and carbamazepine, for example, can reduce the anticoagulant response. Some medications, including NSAIDs and antiplatelet drugs, can increase bleeding risk without producing a proportional increase in INR.

That means the mnemonic “warfarin has no friends” is useful as a reminder to investigate interactions—but not as a prediction that every new drug will increase the INR. Warfarin labeling advises more frequent PT/INR monitoring when interacting or previously unstudied medications are started or stopped. (DailyMed)

The Board Trap

“Check the INR in three to five days” may be a reasonable option in a specific scenario, but there is no universal monitoring interval for every interaction.

The safest general answer is:

Recognize the interaction, communicate with the anticoagulation prescriber or clinic, and arrange earlier or more frequent INR monitoring.

Memory Hook

New medication = new INR plan.

Do not assume the direction. Determine whether the interaction raises anticoagulation, lowers it, or increases bleeding through another mechanism.

4. Levothyroxine: Absorption Depends on How the Patient Takes It

The Typical Question

A patient’s TSH remains elevated despite reporting perfect adherence to levothyroxine. The patient takes the medication every morning with breakfast, calcium, and an iron-containing multivitamin.

What is the most likely problem?

The Best Answer

Improper administration is reducing levothyroxine absorption.

Levothyroxine should generally be taken:

As one daily dose
On an empty stomach
Thirty to 60 minutes before breakfast
With a full glass of water
At least four hours before or after medications and supplements that interfere with absorption

Calcium, iron, and certain antacids are especially common board-test examples. (DailyMed)

What the Question Is Really Testing

The patient may be taking every dose and still not be taking the medication correctly.

Before assuming treatment failure or increasing the dose, look for:

Food taken with the medication
Calcium or iron supplements
Antacids
Inconsistent administration times
A change in medication formulation or interacting therapy

The Board Trap

“Take it every morning” is incomplete counseling.

The patient who swallows levothyroxine with coffee, breakfast, calcium, and six other medications may be adherent but poorly absorbed.

Memory Hook

Levo is a DIVA:

Alone. Empty stomach. First thing. No close friends for four hours.

5. Fluoroquinolones: Tendon Pain Is a Stop Signal

The Typical Question

An older adult taking levofloxacin develops new Achilles tendon pain. The patient also takes prednisone.

What should the NP recommend?

The Best Answer

Stop the fluoroquinolone, avoid exercise or use of the affected tendon, and arrange prompt clinical evaluation. An alternative non-fluoroquinolone antibiotic may be required.

Do not tell the patient to finish the prescription and report back only if the tendon ruptures.

Who Is at Higher Risk?

Fluoroquinolone-associated tendinitis and tendon rupture can occur at any age, but risk is higher in patients who:

Are older than 60
Take systemic corticosteroids
Have received a kidney, heart, or lung transplant
Have renal failure
Engage in strenuous physical activity
Have a history of tendon disease

Tendon injury can begin during treatment or appear after the antibiotic has been completed.

The Bigger Boxed Warning

Fluoroquinolone safety warnings are not limited to tendons. The class is also associated with potentially disabling peripheral neuropathy and central nervous system effects, and it can exacerbate weakness in patients with myasthenia gravis. New burning, tingling, numbness, weakness, severe confusion, hallucinations, or tendon symptoms should not be dismissed as routine adverse effects.

Memory Hook

Fluoroquinolones can FLOOR the tendons.

At the first tendon warning:

Stop. Rest. Reassess.

6. SSRIs and Tramadol: Recognize Serotonin Syndrome Before It Escalates

The Typical Question

A patient taking sertraline begins tramadol and develops agitation, diaphoresis, fever, diarrhea, tremor, and hyperreflexia.

What is the likely diagnosis?

The Best Answer

Serotonin syndrome.

Tramadol is not only an opioid analgesic. It also has serotonergic activity. Combining it with an SSRI, SNRI, tricyclic antidepressant, MAOI, or another serotonergic medication can increase serotonin-syndrome risk. Tramadol can also increase seizure risk, another reason the medication history matters.

The Three Finding Groups

Serotonin syndrome typically combines findings from three categories:

Mental-status changes: agitation, confusion, hallucinations, or coma

Autonomic instability: tachycardia, labile blood pressure, diaphoresis, hyperthermia, vomiting, or diarrhea

Neuromuscular excitation: tremor, hyperreflexia, rigidity, incoordination, or clonus

Symptoms often begin within hours to several days after a serotonergic medication is added, increased, or combined with another serotonergic agent. Suspected serotonin syndrome requires discontinuation of the offending medication and urgent clinical evaluation. (FDA Access Data)

The Board Trap

Do not focus only on fever.

The most revealing clues are often hyperreflexia, clonus, tremor, and agitation after a medication change.

Memory Hook

MAN is hot and twitchy:

Mental-status changes
Autonomic instability
Neuromuscular excitation

7. Beta-Blockers: Chronic Therapy Should Not Be Stopped Abruptly

The Typical Question

A patient wants to stop metoprolol because the blood pressure is now controlled and the patient “feels fine.”

What should the NP advise?

The Best Answer

Do not discontinue chronic beta-blocker therapy without a supervised plan. When metoprolol is being discontinued, the dose is generally reduced gradually over one to two weeks, particularly in patients with ischemic heart disease.

Abrupt cessation can produce worsening angina and, in some cases, myocardial infarction. (DailyMed)

Why Withdrawal Can Be Dangerous

Long-term beta-blockade can produce increased beta-receptor sensitivity. Suddenly removing the blockade may lead to excessive sympathetic activity, with:

Tachycardia
Increased blood pressure
Increased myocardial oxygen demand
Recurrent or worsening angina
Ischemic events in vulnerable patients

The Important Nuance

“Never stop a beta-blocker” is too absolute. Severe bradycardia, shock, or another acute contraindication may require immediate clinical management.

The board-relevant principle is:

A stable patient should not independently stop chronic beta-blocker therapy simply because symptoms or blood pressure have improved.

Memory Hook

Beta-blockers are clingy—you have to break up slowly.

8. Spironolactone Plus an ACE Inhibitor: Monitor the Potassium, Not Just the Blood Pressure

The Typical Question

A patient with heart failure takes lisinopril and is starting spironolactone.

Which laboratory values are most important?

The Best Answer

Check serum potassium and renal function.

Both ACE inhibitors and spironolactone can increase potassium. Used together, they increase hyperkalemia risk, especially in patients with chronic kidney disease, diabetes, dehydration, or other potassium-raising medications.

Spironolactone labeling recommends checking potassium within one week of initiation or dose titration and regularly thereafter. More frequent monitoring may be needed when it is combined with an ACE inhibitor, ARB, trimethoprim, NSAID, potassium supplement, or another drug that raises potassium. (DailyMed)

The Board Trap

The combination is not automatically inappropriate.

Spironolactone or eplerenone can be an important part of guideline-directed therapy for heart failure with reduced ejection fraction. Contemporary heart-failure guidance generally supports mineralocorticoid receptor antagonist therapy when eGFR is greater than 30 mL/min/1.73 m² and serum potassium is below 5 mEq/L—with close follow-up monitoring. (American College of Cardiology)

The correct answer is therefore usually not “never combine them.” It is:

Confirm the patient is an appropriate candidate and monitor potassium and renal function closely.

Also ask about potassium supplements and potassium-containing salt substitutes.

Memory Hook

ACE + SPIRO can send potassium SKY-high.

Think:

Baseline labs → one-week check → regular monitoring.

9. Methotrexate: Folate Matters, but Weekly Dosing Is the Bigger Safety Pearl

The Typical Question

A patient takes low-dose methotrexate for rheumatoid arthritis and develops nausea and mouth sores.

Which supplement is commonly prescribed?

The Best Answer

Folic acid—or, in some regimens, folinic acid—is used to reduce methotrexate adverse effects in patients treated for non-neoplastic diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriasis.

The exact folate product, dose, and schedule should follow the prescribing clinician’s regimen. Do not treat folic acid and leucovorin as casually interchangeable in every patient or disease context. (DailyMed)

The More Dangerous Board Concept

Low-dose methotrexate for rheumatoid arthritis is generally taken once weekly, not daily.

Medication errors in which patients took a weekly methotrexate dose every day have caused fatal toxicity. Whenever methotrexate appears in a question, verify the dosing frequency before focusing on anything else. (DailyMed)

What Should Be Monitored?

Methotrexate can cause myelosuppression, hepatotoxicity, renal toxicity, infection, mucositis, and pulmonary toxicity. Baseline and periodic monitoring commonly includes:

Complete blood count
Liver tests
Renal function

New fever, infection, unusual bruising, severe mouth sores, persistent vomiting or diarrhea, jaundice, or a new dry cough with dyspnea requires prompt evaluation. (DailyMed)

Memory Hook

Metho-TAKES folate; folic acid GIVES support back.

But the lifesaving reminder is:

Methotrexate Monday—not methotrexate every morning.

10. Statins and Muscle Pain: Do Not Treat Every Ache as Rhabdomyolysis

The Typical Question

A patient taking atorvastatin reports diffuse muscle aches.

What should the NP do next?

The Best Answer

The response depends on symptom severity.

Mild to Moderate Symptoms

For tolerable aches without profound weakness, dark urine, fever, or systemic illness:

Review when the symptoms began
Assess whether they are bilateral and involve large proximal muscles
Review the dose and interacting medications
Evaluate other causes, including hypothyroidism, renal or hepatic dysfunction, rheumatologic disease, strenuous exercise, and other muscle disorders
Consider temporarily holding the statin while symptoms are evaluated
Consider CK measurement when clinically appropriate

If symptoms resolve, a lower dose, a rechallenge, or a different statin may allow the patient to continue receiving cardiovascular benefit.

Severe Symptoms or Rhabdomyolysis Warning Signs

If the patient has severe muscle pain, marked weakness, profound fatigue, dark urine, fever, or malaise:

Stop the statin promptly
Obtain CK
Check creatinine
Obtain urinalysis for myoglobinuria
Assess for rhabdomyolysis and acute kidney injury

Current atorvastatin labeling recommends discontinuation when CK is markedly elevated or when myopathy is diagnosed or suspected. (ACC Tools)

The Board Trap

“Muscle pain equals rhabdomyolysis” is incorrect.

Statin-associated muscle symptoms can occur without CK elevation. CK should not be measured routinely in every asymptomatic patient, but it is reasonable in patients with muscle symptoms and particularly important when symptoms are severe. (ACC Tools)

The goal is not to permanently stop all statin therapy at the first mild ache. The goal is to identify dangerous muscle injury, investigate competing causes, and find a tolerable treatment strategy when possible.

Memory Hook

Mild ache: evaluate. Severe weakness or dark urine: stop and investigate.

CK is one piece of the assessment—not the entire diagnosis.

The Pattern Behind These Questions

Notice what these concepts have in common.

The most important information is not simply the name of the drug. It is the decision point:

Medication situation	What the question is testing
Lisinopril plus dry cough	Change the drug class
ACE inhibitor plus facial or tongue swelling	Stop and treat as potential airway emergency
Metformin plus contrast	Check kidney function, route, and protocol
Warfarin plus a new medication	Create a new INR-monitoring plan
Levothyroxine plus calcium or iron	Correct administration and absorption
Fluoroquinolone plus tendon pain	Stop, rest, and evaluate
SSRI plus tramadol symptoms	Recognize serotonin syndrome
Chronic beta-blocker discontinuation	Taper under supervision
ACE inhibitor plus spironolactone	Monitor potassium and renal function
Methotrexate for rheumatoid arthritis	Folate supplementation and once-weekly dosing
Statin plus muscle symptoms	Separate mild intolerance from dangerous myopathy

That is how you should organize your pharmacology review.

A Five-Step Method for Answering Pharm Questions

When a medication question appears, work through the same sequence:

1. Identify the Drug Class

Do not stop at the generic name. Translate it into a class:

Lisinopril → ACE inhibitor
Losartan → ARB
Spironolactone → mineralocorticoid receptor antagonist and potassium-sparing diuretic
Sertraline → SSRI
Atorvastatin → statin

The class often reveals the adverse effect or interaction.

2. Identify What Changed

Look for:

A new medication
A dose increase
A new symptom
A new abnormal laboratory result
Declining renal or hepatic function
Pregnancy
A planned procedure

Medication questions usually contain a change that creates the problem.

3. Decide Whether the Finding Is Expected or Dangerous

Expected findings may require counseling or monitoring.

Dangerous findings may require holding the medication, stopping it, obtaining urgent testing, or sending the patient for emergency evaluation.

For example:

ACE inhibitor cough → change therapy
ACE inhibitor angioedema → airway concern
Mild statin ache → evaluate
Severe weakness and dark urine → evaluate for rhabdomyolysis

4. Choose the Safest Immediate Action

Ask what needs to happen first:

Continue and reassure?
Counsel on administration?
Order a laboratory test?
Hold a dose?
Taper?
Stop the medication?
Arrange emergency care?

Do not jump to long-term treatment before addressing immediate safety.

5. Look for the Monitoring Parameter

Many pharmacology questions become easier when you pair the drug with its key monitoring issue:

Warfarin → INR
Spironolactone → potassium and renal function
Methotrexate → CBC, liver tests, and renal function
Levothyroxine → TSH after an appropriate interval
Severe statin muscle symptoms → CK, creatinine, and urinalysis

What Not to Do When Studying Pharmacology

Do not try to memorize every adverse effect in alphabetical order.

Instead, build a one-page framework for each major drug class:

Drug or class: What medications belong to it?

Primary use: Why is the patient taking it?

Must-not-miss reaction: What could seriously harm the patient?

Common expected effect: What can be managed or monitored?

Key interaction: What medication combination appears on exams?

Monitoring: What symptom, vital sign, or laboratory value matters?

Patient teaching: What instruction prevents an adverse event?

Hold or stop rule: What finding changes management immediately?

That structure turns pharmacology from a memory contest into clinical reasoning.

Lock These Concepts In

Our Pharmacology Flashcards 👉 The Pharmacology Flashcards → use this same format across more than 200 high-yield concepts:

The board-style question pattern
The clinical decision being tested
The correct action
The common distractor
The monitoring parameter
A memory hook designed to stick under pressure

Because remembering that a medication causes an adverse effect is only the first step.

To get the question right, you need to know what to do about it.